# Aflac (AFL) Q2 2026 earnings

Results filed 2026-08-06 for the quarter ended 2026-06-30. Source page: https://earnings.opennash.com/companies/afl/2026-q2/
Press release and documents: https://www.sec.gov/Archives/edgar/data/4977/000162828026054333/0001628280-26-054333-index.htm
> Summaries and transcripts are machine-generated and can contain errors.

## In brief

Aflac Japan's new Anshin Palette medical and refreshed Tsumitasu life products drove growth, offsetting a high Miraito cancer comparison, while U.S. sales gained from group voluntary benefits and network dental and vision.

Aflac's product launches in Japan are the main business story. Anshin Palette, a new medical insurance product launched in December 2025, and the refreshed Tsumitasu savings-type life insurance grew strongly. Japan sales fell 5.6% for the quarter only because Miraito cancer insurance, launched in March 2025, set a high bar. In the U.S., sales rose 2.6%, helped by group voluntary benefits and network dental and vision products.
Management is steering toward more profitable growth, more reinsurance in Japan, and a push to get brokers to adopt network dental in the second half. Aflac Japan's reinsurance target is now up to 30% of FSA reserves, aiming for a higher return on equity. The tension is that new products are bringing somewhat elevated lapse and reissue activity in Japan, while U.S. premium growth for 2026 is now expected just below its guided range.

## Key numbers

| Metric | Value | Change | Basis |
| --- | --- | --- | --- |
| Total revenues | $4.1 billion | down 1.0% from a year ago | GAAP |
| Net earnings | $825 million | up from $599 million a year ago | GAAP |
| Net earnings per diluted share | $1.63 | up from $1.11 a year ago | GAAP |
| Adjusted earnings per diluted share | $1.75 | down 1.7% from a year ago | non-GAAP |
| Adjusted earnings | $883 million | down 7.7% from a year ago | non-GAAP |

## Segments and operating metrics

| Name | Value | Change |
| --- | --- | --- |
| Aflac Japan new annualized premium sales | ¥19.6 billion | down 5.6% |
| Aflac U.S. sales | $349 million | up 2.6% |
| Aflac Japan premium persistency | 92.7% | down 100 bps |
| Aflac U.S. persistency | 79.4% | up 20 bps |

## Outlook

| Metric | Period | Outlook |
| --- | --- | --- |
| Aflac Japan benefit ratio, high end of range | full year 2026 | 60% to 63% |
| Aflac Japan expense ratio | 2026 | 20% - 23% |
| Aflac Japan pretax profit margin | 2026 | 33% - 36% |
| Aflac U.S. benefit ratio | 2026 | 48% - 52% |
| Aflac U.S. expense ratio | 2026 | 36% - 39% |
| Aflac U.S. pretax profit margin | 2026 | 17% - 20% |
| Aflac U.S. net earned premium growth | 2026 | just below our guidance range of 3% to 6% |
| Aflac U.S. net earned premium CAGR | 2025-2027 | 3% to 6% |

## Key takeaways

1. **Japan's new products offset a tough Miraito comparison** Japan sales fell 5.6% to ¥19.6 billion because Miraito cancer insurance launched in March 2025. Strong growth in the refreshed Tsumitasu and Anshin Palette partly offset that, and first-half sales rose 7.0%.
2. **U.S. sales driven by group and network dental** Aflac U.S. sales increased 2.6% to $349 million, mainly from group voluntary benefits and network dental and vision products. This shows the U.S. business moving toward employer-sponsored bundles.
3. **Japan reinsurance target raised to 30% of FSA reserves** Aflac Japan moved from an internal target of up to 10% of U.S. GAAP assets to up to 30% of FSA reserves. Management says this reduces risk, improves balance sheet efficiency and should lift ROE.
4. **New products create elevated lapse and reissue activity** Japan persistency was 92.7%, with somewhat elevated lapse and reissue activity on recently launched products as coverage options expanded. Lapses on the first sector savings block stayed low despite higher yen interest rates.
5. **U.S. premium growth guided just below range** Management now expects 2026 U.S. net earned premium growth just below its 3% to 6% range, versus the low end before. It still expects the 2025-2027 compound growth rate to land within that range.

## Questions

**Which products drove Aflac Japan's sales this quarter?** Refreshed Tsumitasu savings-type life insurance and Anshin Palette, a medical insurance product launched in December 2025, grew strongly. Miraito cancer insurance, launched in March 2025, faced a high prior-year baseline.
**What is driving Aflac U.S. sales growth?** U.S. sales rose 2.6% to $349 million, mainly from group voluntary benefits and network dental and vision products. Management plans a stronger second-half push to get brokers to adopt network dental.
**How is Aflac changing its reinsurance strategy in Japan?** Aflac Japan raised its reinsurance target to up to 30% of FSA reserves, replacing an internal target of up to 10% of U.S. GAAP assets. Management says it should reduce risk, improve balance sheet efficiency and raise ROE.
**Is customer retention a concern in Japan?** Persistency was 92.7%, in line with expectations, with somewhat elevated lapse and reissue activity on newly launched products. Lapses on the first sector savings block remained low despite higher yen interest rates.
**How did Aflac change its U.S. premium outlook?** It now expects 2026 net earned premium growth just below the 3% to 6% guidance range, versus the low end of the range previously. It still expects the 2025-2027 compound growth rate within the range.

